Acelyrin, Inc. (NASDAQ:SLRN) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Acelyrin, Inc. (NASDAQ:SLRN) have received an average rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $11.50.

A number of research firms have commented on SLRN. Piper Sandler reduced their price target on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. Wells Fargo & Company boosted their target price on Acelyrin from $13.00 to $15.00 and gave the stock an “overweight” rating in a report on Wednesday, October 16th. HC Wainwright raised their price target on Acelyrin from $6.00 to $8.00 and gave the company a “neutral” rating in a report on Thursday, November 14th. Finally, Morgan Stanley reduced their price objective on Acelyrin from $13.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Monday, August 19th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in shares of Acelyrin during the 3rd quarter worth approximately $50,000. Barclays PLC boosted its stake in Acelyrin by 208.8% in the third quarter. Barclays PLC now owns 96,408 shares of the company’s stock valued at $475,000 after acquiring an additional 65,188 shares during the last quarter. Geode Capital Management LLC grew its holdings in Acelyrin by 30.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,651,614 shares of the company’s stock worth $8,144,000 after acquiring an additional 388,631 shares during the period. Public Employees Retirement System of Ohio raised its position in shares of Acelyrin by 54.6% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 102,347 shares of the company’s stock valued at $505,000 after acquiring an additional 36,154 shares during the last quarter. Finally, Virtus Investment Advisers Inc. acquired a new position in shares of Acelyrin in the 3rd quarter valued at $176,000. 87.31% of the stock is currently owned by institutional investors and hedge funds.

Acelyrin Stock Performance

Shares of NASDAQ SLRN opened at $4.35 on Friday. The business has a fifty day moving average of $5.39 and a two-hundred day moving average of $5.03. Acelyrin has a 52-week low of $3.36 and a 52-week high of $8.89. The stock has a market cap of $436.44 million, a PE ratio of -1.77 and a beta of 1.98.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.